Duopharma Biotech Berhad (Duopharma Biotech) reported a revenue of RM931.69 million for the year ended 31 December 2025, up 14.5% compared to revenue of RM813.70 million in financial year 2024. In line with increased revenue, profit for the year also saw robust growth, with profit before tax (PBT) for FY2025 growing 43.6% year-on-year to RM114.91 million, while profit after tax (PAT) for FY2025 went up by 39.6% year-on-year to RM87.46 million.
The sustained double-digit growth was primarily driven by resilient demand from both the public and private sectors across all business segments, complemented by a one- off surge in insulin supply in the first half of the year following supply normalisation. PBT growth was mainly attributable to the higher revenue base, coupled with continued favourable Active Pharmaceutical Ingredient (API) costs, positive foreign exchange movements and improved operational efficiency, which collectively enhanced profitability.
Meanwhile, revenue in Quarter 4 of FY2025 stood at RM224.69 million, marginally higher compared to RM222.49 million in the preceding quarter, spurred by stronger demand from the private market, including a seasonally-influenced sales spike for an antiviral flu product, offsetting lower fourth quarter sales to the public sector.
Wan Amir-Jeffery Bin Wan Abdul Majid, Group Chief Executive Officer of Duopharma Biotech Berhad, commented, “The robust growth in revenue and profit in FY2025 augurs well for Duopharma Biotech’s future potential. The Government’s healthcare policy initiatives and agenda, including 2.7% more healthcare funding year-on-year via Budget 2026 and a focus on improving pharmaceutical research and manufacturing for a stronger supply chain, laid out in the 13th Malaysia Plan, offer the potential for us to participate in achieving national healthcare goals, strengthening our position as a leading Malaysian pharmaceutical player.”
New and Ongoing Contracts
On 16 February 2026, Duopharma Biotech announced that the Government of Malaysia had accepted the tender offer from Duopharma (M) Sendirian Berhad (a wholly-owned subsidiary of Duopharma Biotech) to supply insulin injections to the Ministry of Health’s facilities. The new contract, running until 5 February 2028, has a total estimated value of approximately RM52.54 million. Also on 16 February 2026, Duopharma Biotech announced that Duopharma Marketing Sdn Bhd (a wholly-owned subsidiary of Duopharma Biotech) and Biocon Sdn Bhd to supply Recombinant Human Insulin formulations under the Ministry of Health’s procurement by way of direct negotiation. The new contract will run until 15 May 2026, with a total estimated value of approximately RM65.08 million. The two new contracts are expected to contribute positively to the Company’s future earnings, barring any unforeseen circumstances. This will also contribute to better diabetes management in Malaysia by supplying high quality and cost- effective biosimilar insulin and insulin injections.
As previously announced in 2024 and 2025, Duopharma Biotech is currently contracted to supply 100 products at a combined estimated contract value of approximately RM684.15 million to Ministry of Health facilities, until 31 December 2026.
Wan Amir-Jeffery added, “In FY2025, the Group’s regional operations also recorded encouraging progress through improved market penetration and growing demand in key ASEAN markets. Looking ahead, the new leadership at Duopharma Biotech will remain proactively focused on enhancing operational efficiencies, optimising cost management strategies, and executing strategic initiatives. Barring any unforeseen circumstances, the Group aims to deliver a satisfactory performance for the financial year ending 31 December 2026.”
In addition to Wan Amir-Jeffery taking on the leadership mantle at Duopharma Biotech, Rohayu Rosnani Binti Mohd Adanan has also been appointed the Company’s new Chief Financial Officer.
For FY2025, Duopharma Biotech’s Board of Directors declared a second interim dividend of 3.05 sen per share (2024: 2.0 sen) equivalent to RM 29.34 million (2024: RM 19.24 million). This brings the total dividend for FY2025 to 4.55 sen per share (2024: 3.0 sen), amounting to approximately RM43.77 million, an increase of 51.7% from FY2024. The entitlement date and the payment date of the second interim dividend will be on 13 March 2026 and 30 March 2026 respectively. The Board of Directors has resolved that the Dividend Reinvestment Plan shall not apply to the aforesaid interim dividend.
